Pipeline and Asset Evaluation: Assessment of trial and asset design, Mode of Action, Competiveness including Clinical Development Plans (CDPs), Target Product Profiles (TPPs).

Pipeline Assessment: Reviewing the pharmaceutical pipeline to evaluate the potential success of drug candidates and their fit within the current therapeutic landscape.

Scientific Rigor: Evaluating the robustness of scientific data supporting the drug candidates, including mechanisms of action, biomarker development, and translational research.

Market Viability: Collaborating with commercial teams to understand the clinical relevance of drug candidates in the market context and their potential to meet unmet medical needs.

Clinical assessment for Investment risk and biotech evaluation: Evaluation and Support of VCs, HWNI and Family Offices for assessment of biotech companies, pipelines for viability of asset, executive team composition, including coaching and optimization of team structures, assets and pipelines and proposing mitigation strategies.

Collaboration and Communication: Working closely with biotech executive teams or VC partners for their assets and portfolio companies as clinical advisor in due diligence activities .